ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2076

Oxidation Products Of Arachidonic Acid and Linoleic Acid Are Increased In High Density Lipoprotein From Patients With Dermatomyositis and Polymyositis

Christina Charles-Schoeman1, Yuen Yin Lee1, Ani Shahbazian1, David Meriwether2, Geraldine Navarro1, John D. FitzGerald1 and Srinivasa T. Reddy2, 1Medicine-Rheumatology, UCLA David Geffen School of Medicine, Los Angeles, CA, 2Medicine-Cardiology, UCLA David Geffen School of Medicine, Los Angeles, CA

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: cholesterol and myositis, Lung Disease

  • Tweet
  • Email
  • Print
Session Information

Title: Muscle Biology, Myositis and Myopathies: Advances in the Epidemiology, Immunology and Therapy of Myositis

Session Type: Abstract Submissions (ACR)

Background/Purpose:   Oxidation products of arachidonic acid and linoleic acid including hydroxyeicosatetraenoic acids (HETEs) and hydroxyoctadecadienoic acids (HODEs), respectively, play an important role in the pathogenesis of atherosclerosis and have been associated with endothelial cell activation.  HETEs and HODEs contribute to the oxidation of low density lipoprotein (LDL) and their accumulation in high density lipoprotein (HDL) impairs HDL function, which increases risk of vascular damage.  The current work evaluated the levels of HETEs and HODEs in HDL isolated from patients with dermatomyositis (DM) and polymyositis (PM) since vascular damage is implicated in the pathogenesis of both muscle and lung disease in DM/PM patients,

Methods: HDL was isolated by ultracentrifugation from plasma of 12 DM patients, 12 PM patients and 12 healthy controls. 5-HETE, 12-HETE, 15-HETE, 9-HODE, and 13-HODE levels in HDL were measured by mass spectrometry as described previously (Imaizumi et al. Drug Metab Lett. 2010; 4(3): 139-48). HDL’s anti-inflammatory function was measured by a cell free assay as described previously (Charles-Schoeman et al. Arthritis Rheum. 2009; 60(10): 2870-9). Lipoprotein cholesterol levels were determined by standard methods.

Results: 5-HETE, 15-HETE, 9-HODE and 13-HODE levels were significantly increased in HDL from patients with PM compared to healthy controls (see Table).  5-HETE was also significantly increased in HDL from DM patients compared to controls and was significantly correlated with the HDL inflammatory index (r = 0.41, p=0.01); higher HDL-associated 5-HETE was associated with worse anti-oxidant capacity of HDL.  Myositis patients with interstitial lung disease (ILD) (n=14) had higher 13-HODE, 12-HETE, and 5-HETE levels in HDL compared to myositis patients without ILD (n=10) (p values= 0.05, 0.06, and 0.13 respectively). Patients with moderate to severe ILD suggested by the diffusing capacity of the lungs for carbon monoxide (DLCO) <50% of predicted also showed trends for higher HDL-associated 5-HETE, 12-HETE, and 13-HODE levels compared to ILD patients with less severe disease (DLCO >50%) (see Table). 5-HETE and 12-HETE levels were inversely correlated with DLCO, r = -0.58 (p=0.02) and r = -0.49 (p=0.05), respectively. 

Conclusion:   Oxidation products of arachidonic acid and linoleic acid are increased in HDL from patients with PM and DM compared to healthy controls.  Increased 5-HETE in HDL was associated with impaired HDL anti-oxidant function and was inversely associated with DLCO in patients with myositis. Our results suggest that therapeutic agents such as apoA-I mimetic peptides, which bind oxidized fatty acids and reduce vascular damage and lung injury in animal models, may warrant further investigation in DM/PM patients.

 

Healthy Control (n=12)

Polymyositis

(n=12)

Dermatomyositis

 (n=12)

Age (years)

48 ± 13 

52 ± 8

49 ± 9

Sex (% female)

67% 

58%

83%

Ethnicity (% hispanic)

42% 

45%

17%

Total Cholesterol (mg/dL)

184 ± 28   

204 ± 50

191 ± 39

LDL Cholesterol (mg/dL)

112 ± 25  

113 ± 51

122 ± 39

HDL Cholesterol (mg/dL)

55 ± 13  

67 ± 39

52 ± 13

Triglycerides (mg/dL)

90 ± 39

156 ± 54*

124 ± 54

ESR  (mm/hr)

6 ± 7    

38 ± 23*

50 ± 27*

HS-CRP (mg/L)

0.6 ± 0.5    

7.9 ± 8.9*

12.2 ± 13.2*

HDL Inflammatory Index (HII)

0.80± 0.15*   

1.20 ± 0.42*

1.49 ± 0.67*

5-HETE (pg/75μg HDL-C)

12721 ± 4493

65125 ± 18732*

32460 ± 28569*

12-HETE (pg/75μg HDL-C)

321 ± 234   

585 ± 406

810 ± 831

15-HETE (pg/75μg HDL-C)

12 ± 9   

36 ± 22*

18 ± 15

9-HODE (pg/75μg HDL-C)

57 ± 97   

213 ± 167*

110 ± 110

13-HODE (pg/75μg HDL-C)

158 ± 111   

472 ± 149*

308 ± 355

                ILD (n=14)

             No ILD (n=10)

5-HETE (pg/75μg HDL-C)

54968 ± 25630

40147 ± 32351

12-HETE (pg/75μg HDL-C)

938 ± 766   

362 ± 136

13-HODE (pg/75μg HDL-C)

481 ± 279   

263 ± 236

ILD (DLCO <50) (n=6)

ILD (DLCO ≥ 50) (n=7)

5-HETE (pg/75μg HDL-C)

64867 ± 24687

53143 ± 21244

12-HETE (pg/75μg HDL-C)

1117 ± 658   

542 ± 466

13-HODE (pg/75μg HDL-C)

567 ± 319   

357 ± 192

All values mean ± standard deviation.  *p value ≤ 0.05 compared to controls.

Note: Recent DLCO value not available for one patient with known ILD.


Disclosure:

C. Charles-Schoeman,
None;

Y. Y. Lee,
None;

A. Shahbazian,
None;

D. Meriwether,
None;

G. Navarro,
None;

J. D. FitzGerald,
None;

S. T. Reddy,
None.

  • Tweet
  • Email
  • Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/oxidation-products-of-arachidonic-acid-and-linoleic-acid-are-increased-in-high-density-lipoprotein-from-patients-with-dermatomyositis-and-polymyositis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology